Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX000197 in Malignant Pleural Effusion
NCT06740019Phase 1Recruiting
- Sponsor
- Jemincare
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JMKX000197 in malignant pleural effusion (MPE) (3 arms), sponsored by Jemincare. Primary endpoints: Adverse Events and Recommended Phase II Dose. Started Dec 2024; status: recruiting.
02
Drugs
JMKX000197
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT06740019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740019.